List view / Grid view
11 May 2021 | By PerkinElmer
Get the Big Picture and listen to Pharma thought leaders how they view CETSA® and its impact on their Drug Discovery.
Researchers have produced a computational simulation of the SARS-CoV-2 Spike protein, finding spots that glycans do not cover.
Researchers have found that over 80 percent of antibodies target sections of the SARS-CoV-2 Spike protein other than the RBD.
Gain more insight into immune-tumor interactions and learn how antibody detection techniques like multiplexing is advancing immunotherapies.
Summary of a neurology publication by Alnylam Pharmaceuticals: large-scale protein screening identifies novel biomarker for onset and progression of lethal ATTRv amyloidosis.
In this short video we show an example of a 3D airway organoid model along with some interesting ways to get the most out of this type of assay.
A new antibody cocktail made from three mAbs neutralised several SARS-CoV-2 variants in pre-clinical studies.
Researchers have used cryo-EM to show that a new nanobody cocktail can bind to the S protein of SARS-CoV-2, neutralising the coronavirus.
Accelerate your research with an upgradeable platform. Benefit from a fluidic-free assay format for easy and fast kinetics or analyte quantitation.
5,000+ drug target reagents for antibody, small molecule drug discovery and development, including immune checkpoints, cytokines and kinases.
Researchers have developed an artificial intelligence to identify the best potential antibody drug from groups of up to a few thousand.
Dr Brittany Busse discusses why COVID-19 can influence the onset of diabetes and how this could shape the development of therapeutics.
14 April 2021 | By Fluidigm
Watch our free on-demand webinar to learn more about using Imaging Mass Cytometry™ (IMC™) to measure over 40 protein targets with subcellular resolution.
Using cryo-electron microscopy, researchers have shown that the Spike (S) protein on cells exposed to the AstraZeneca vaccine is highly similar to the SARS-CoV-2 S protein.
A model of the SARS-CoV-2 Spike protein surface has uncovered vulnerabilities that researchers say could inform the development of COVID-19 vaccines.
